This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Alkermes (ALKS) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Alkermes (ALKS) delivered earnings and revenue surprises of -25.42% and 2.75%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Deciphera Pharmaceuticals, Inc. (DCPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Deciphera Pharmaceuticals (DCPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition?
by Zacks Equity Research
Alkermes (ALKS) expects its set of proprietary products, Vivitrol, Aristada and Lybalvi, to generate incremental sales and combat stiff competition in 2024.
Alkermes (ALKS) Earnings Expected to Grow: What to Know Ahead of Q1 Release
by Zacks Equity Research
Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study
by Zacks Equity Research
Alkermes (ALKS) reports positive top-line data from a phase Ib, proof-of-concept study investigating ALKS 2680 for the treatment of narcolepsy.
Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Alkermes (ALKS) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Alkermes (ALKS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Alkermes (ALKS) Stock Moves -0.45%: What You Should Know
by Zacks Equity Research
In the most recent trading session, Alkermes (ALKS) closed at $28.75, indicating a -0.45% shift from the previous trading day.
3 Reasons Why Alkermes (ALKS) Is a Great Growth Stock
by Zacks Equity Research
Alkermes (ALKS) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Here's Why Alkermes (ALKS) is a Strong Momentum Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Alkermes (ALKS) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Alkermes (ALKS) Outpaced the Stock Market Today
by Zacks Equity Research
Alkermes (ALKS) concluded the recent trading session at $29.45, signifying a +1.76% move from its prior day's close.
Alkermes (ALKS) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
In the closing of the recent trading day, Alkermes (ALKS) stood at $29.69, denoting a -0.37% change from the preceding trading day.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Why Alkermes (ALKS) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Alkermes' (ALKS) Q4 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Alkermes' (ALKS) earnings and revenues outpace estimates in the fourth quarter of 2023. Strong growth in proprietary products drives year-over-year revenues.
Compared to Estimates, Alkermes (ALKS) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Alkermes (ALKS) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On CRISPR's (CRSP) fourth-quarter 2023 earnings call, investors' focus is likely to be on the company's progress with the launch activities of the newly approved gene therapy, Casgevy (exa-cel).
Halozyme Therapeutics (HALO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.